Karman Holdings: Stock Tripled From IPO While PE Sponsor Exited in 5 Months and Every Executive Started Selling
42% revenue growth, $758M funded backlog, and flight-qualified content on 130+ defense programs. The business case is strong. The capital structure and insider behavior add complexity.
Up 42% YoY, record quarter
100% visibility to guidance
~3x EBITDA, PE-legacy leverage
vs $38M adjusted EBITDA (5x gap)
Karman Holdings (KRMN) is a defense and space subsystems company that IPO'd at $22/share in February 2025 and roughly tripled within a year. The company positions itself as a “merchant supplier to virtually every prime contractor” in the U.S. defense industrial base, providing mission-critical components for missiles, rockets, and hypersonic systems.
The numbers are compelling: revenue grew 42% in Q3, funded backlog hit $758M (providing 100% visibility to guidance), and gross margins expanded to 41%. Management has raised guidance three consecutive quarters and is projecting 20-25% organic growth for FY2026.
The complications are equally notable. PE sponsor Trive Capital fully exited within 5 months of the IPO, realizing a 3x+ return. Every C-suite officer adopted selling plans and began disposing of shares. The $505M term loan consumes 80% of operating income through interest expense, creating a 5x gap between management's preferred EBITDA metric and GAAP net income.
Want the full 7-lens analysis with signal assessments and model debates?
Opus + Sonnet ensemble. 7 lenses. 10 signals. 11 debates. Full evidence citations.
Signal Dashboard
Flight qualification barriers on 130+ programs create structural switching costs. Breadth across composites, energetics, propulsion, and metallurgy is genuinely differentiated.
$758M funded backlog provides extraordinary visibility, but revenue depends on continued defense spending momentum. No single program >11%.
Current performance data validates the growth narrative. Three consecutive guidance raises build credibility. Forward claims (Golden Dome, hypersonics) remain aspirational.
Standard defense industry accounting with ship-and-invoice revenue recognition on 90%+ fixed-price contracts. No aggressive adjustments identified.
$505M term loan with 2032 maturity removes refinancing risk, but interest expense consumes 80% of operating income. Cash on hand just $19M.
Three acquisitions in year one add complementary capabilities but strain bandwidth. G&A growing 79% vs 42% revenue growth. Leverage rising.
All 5 C-suite officers selling under coordinated 10b5-1 plans. PE sponsor fully exited in 5 months. CEO retains $150M+ in stock.
Stock tripled from $22 IPO to ~$65. Valuation requires 20-25% organic growth for multiple years. Any deceleration triggers re-rating.
Key Findings
The Competitive Moat Is Structural, Not Cyclical
Karman's flight-qualified content on 130+ programs creates switching costs that persist regardless of the defense spending environment. Requalifying a component on a missile or rocket system requires 12-24 months of testing. The company's breadth across product categories (payload protection, propulsion, thermal systems, exotic alloys) makes it a multi-capability partner rather than a single-function shop.
When analyst Ken Herbert directly asked about dual-sourcing risk, CEO Koblinski flatly denied any displacement efforts: “We don't give our customers a reason to switch.” The committee assessed this claim as credible for existing programs but noted that dual-sourcing applies primarily to new program starts where capacity is the bottleneck.
The EBITDA vs. Net Income Gap Reveals the True Cost Structure
Management presents adjusted EBITDA ($38M/quarter, ~31% margin) as the primary profitability metric. GAAP net income is $7.6M (6.3% margin). The 5x gap is driven by $10M/quarter interest expense and $8.1M/quarter D&A from acquisition intangibles.
How management presents profitability
What shareholders actually earn
Trive Capital's Full Exit in 5 Months and Coordinated C-Suite Selling
PE sponsor Trive Capital sold its entire position between the February 2025 IPO ($22/share) and the July 2025 secondary ($49/share), realizing a 3x+ return. Then all five C-suite officers adopted 10b5-1 plans in August and began selling in November. CEO Koblinski disposes of 75,000 shares per week.
The committee debated whether this signals concern or standard practice. The resolution: each individual action is explainable (fund lifecycle, post-IPO diversification, pre-planned trading). But the aggregate pattern of broad, rapid liquidity realization at premium prices warrants ongoing monitoring. The CEO's retained position of ~2.3M shares ($150M+) provides meaningful continued alignment.
Three Acquisitions in Year One: Capability Building or PE Playbook?
MTI, ISP, and Five Axis Industries were acquired within 12 months of the IPO, each funded by incremental term loan draws. Five Axis adds exotic alloy nozzle manufacturing for liquid-fueled rocket engines. Management targets 1-2 tuck-in acquisitions per year.
The committee found the acquisitions to be genuinely capability-additive (extending product categories from composites and energetics into exotic metallurgy). The CEO claims proprietary, non-auction deal flow. However, G&A expenses grew 79% versus 42% revenue growth, signaling integration overhead. The MTI/ISP integration is on schedule for mid-2026 completion.
Where Models Disagreed
Is Trive Capital's Exit a Red Flag or Standard PE Practice?
Five-month exit is unusually rapid. Could signal insider knowledge of peak conditions or awareness of challenges not yet visible to public investors.
Standard PE fund lifecycle dynamics. Trive Fund III was likely approaching maturity. The $1.2B secondary at $49 required strong institutional demand, which validates the company's value.
Converged on fund lifecycle as the primary driver, but flagged that the complete exit (including in-kind distributions to LPs) means zero ongoing economic interest from the founding sponsor.
Is the Competitive Moat Structural or Amplified by the Defense Cycle?
Flight qualification barriers persist regardless of spending cycles. Breadth across product categories is genuinely differentiated among Tier 2 suppliers.
The 42% growth rate reflects the defense spending supercycle more than structural advantage. A spending plateau would test whether the moat sustains pricing power.
Converged on DEFENSIBLE: Switching costs are structural, but the magnitude of advantage is amplified by current spending momentum. A spending plateau would reduce growth to single digits without eliminating the moat.
Are Unit Economics Proven or Just Plausible?
One year of public data is insufficient. Each acquisition introduces cost structures that may not match Karman's efficiency baseline. PLAUSIBLE is the ceiling.
Gross margins expanded from 37.6% to 41% across 7 quarters. EBITDA margins stable at ~31% despite 3 acquisitions. The trend supports PROVEN.
Settled on PLAUSIBLE: Margins are strong and improving, but one year of public data with acquisition-driven growth is insufficient for PROVEN. The 50bps annual margin expansion target requires 2-3 more quarters of validation.
Cross-Lens Reinforcements
3 lenses (Moat Mapper, Prospectus Probe, Stress Scanner) converge: flight qualification barriers, breadth-based positioning, and domestic manufacturing base create genuine structural advantages.
3 lenses (Stress Scanner, Consolidation Calibrator, Fugazi Filter) identify the $505M term loan as the central risk factor. Interest expense consumes most operating income.
2 lenses (Insider Investigator, Prospectus Probe) agree: selling is transparent and planned, but the breadth and velocity create mixed optics despite substantial retained positions.
2 lenses (Myth Meter, Prospectus Probe) confirm: current performance substantiates the growth story with verifiable data. Forward claims (Golden Dome, hypersonics) remain aspirational.
What to Watch
Currently ~3.0x pro forma EBITDA. Each acquisition adds debt. A move above 3.5x for two consecutive quarters would warrant reassessment of the leverage thesis.
Currently 42% in Q3, 34% guided full year. Growth below 15% for any quarter without obvious one-time factors would challenge the valuation thesis and growth premium.
Management references Golden Dome extensively but no specific contract awards have been attributed to the program. Tangible POs or extended funding delays would both change the forward thesis.
Currently disposing of 75,000 shares/week at $58-69. Any acceleration, plan modification, or new plan adoption would warrant re-evaluation of insider sentiment.
PROCEED WITH CAUTION
Karman Holdings has a genuinely defensible competitive position in a growing defense market, with structural switching costs and extraordinary revenue visibility. The business fundamentals are strong. The capital structure and insider behavior add complexity that requires careful monitoring through the company's transition from PE-backed growth vehicle to standalone public compounder.
Path to More Favorable Assessment
- • Leverage declines from 3x toward 2.5x EBITDA
- • FY2026 organic growth confirms 20-25% CAGR target
- • G&A normalizes below 14% of revenue post-integration
- • Golden Dome materializes into specific contract awards
- • First DEF14A shows strong compensation alignment
Path to Less Favorable Assessment
- • Leverage exceeds 3.5x from additional acquisition debt
- • Revenue growth decelerates below 15% for any quarter
- • Insider selling accelerates beyond current 10b5-1 plans
- • Dual-sourcing announced on a program Karman currently supports
- • Defense spending growth stalls or reverses
This analysis is for educational purposes only. It is not a recommendation to buy or sell any security.
Public Sources Used (18 documents)
• Annual Report (10-K) — FY2024
• Quarterly Reports (10-Q) — Q1, Q2, Q3 FY2025
• IPO Prospectus (S-1) — January 2025 (initial filing)
• IPO Prospectus (S-1) — July 2025 (amendment)
• Current Reports (8-K) — 10 filings covering earnings, acquisitions, CEO transition
• Q1 FY2025 Earnings Call Transcript
• Q3 FY2025 Earnings Call Transcript
• Form 4 Insider Transactions — 20 filings
• Form 144 Proposed Sales — 5 filings
Full Analysis with Signal Breakdowns
Explore the complete 7-lens assessment including debate transcripts, evidence citations, and monitoring triggers for Karman Holdings.
View KRMN Analysis